Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 17/20 | 0.60 |
| ▸ | OXTR | P30559 | 11/20 | 0.60 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.60 |
| ▸ | TSPO | P30536 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30045753 | 1.00 | AVPR1A (0.60) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL26185550 | 1.00 | AVPR1A (0.60) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL26564181 | 0.89 | AVPR1A (0.58) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL20277678 | 0.88 | AVPR1A (0.57) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL30047020 | 0.88 | AVPR1A (0.68) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL20276925 | 0.88 | AVPR1A (0.68) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL30046935 | 0.87 | AVPR1A (0.67) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL26185552 | 0.87 | AVPR1A (0.67) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL30045852 | 0.87 | AVPR1A (0.55) | AVPR1AOXTRAVPR2 | |
| SCHEMBL26185558 | 0.87 | AVPR1A (0.55) | AVPR1AOXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491165-B2 | Non-peptide oxytocin receptor agonists | Kinoxis Therapeutics Pty Ltd (AU) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491165-B2 | Non-peptide oxytocin receptor agonists | OXTR, AVPR1B, AVPR1A | AVPR1A 3/4885OXTR 1/4885AVPR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.